company background image
300639 logo

Guangdong Hybribio BiotechLtd SZSE:300639 Stock Report

Last Price

CN¥6.96

Market Cap

CN¥4.4b

7D

-7.8%

1Y

-39.2%

Updated

27 Mar, 2024

Data

Company Financials +

Guangdong Hybribio Biotech Co.,Ltd.

SZSE:300639 Stock Report

Market Cap: CN¥4.4b

300639 Stock Overview

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes.

300639 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance1/6
Financial Health5/6
Dividends4/6

Guangdong Hybribio Biotech Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Guangdong Hybribio BiotechLtd
Historical stock prices
Current Share PriceCN¥6.96
52 Week HighCN¥11.91
52 Week LowCN¥5.65
Beta0.48
1 Month Change-5.82%
3 Month Change-24.76%
1 Year Change-39.23%
3 Year Change-42.19%
5 Year Change11.98%
Change since IPO77.62%

Recent News & Updates

Recent updates

Shareholder Returns

300639CN BiotechsCN Market
7D-7.8%-4.9%-2.2%
1Y-39.2%-20.7%-14.8%

Return vs Industry: 300639 underperformed the CN Biotechs industry which returned -20.7% over the past year.

Return vs Market: 300639 underperformed the CN Market which returned -14.8% over the past year.

Price Volatility

Is 300639's price volatile compared to industry and market?
300639 volatility
300639 Average Weekly Movement6.8%
Biotechs Industry Average Movement8.0%
Market Average Movement8.1%
10% most volatile stocks in CN Market11.4%
10% least volatile stocks in CN Market5.1%

Stable Share Price: 300639's share price has been volatile over the past 3 months.

Volatility Over Time: 300639's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20032,733Jianyu Wanghttps://www.hybribio.cn

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal.

Guangdong Hybribio Biotech Co.,Ltd. Fundamentals Summary

How do Guangdong Hybribio BiotechLtd's earnings and revenue compare to its market cap?
300639 fundamental statistics
Market capCN¥4.45b
Earnings (TTM)CN¥409.39m
Revenue (TTM)CN¥2.19b

10.9x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300639 income statement (TTM)
RevenueCN¥2.19b
Cost of RevenueCN¥787.65m
Gross ProfitCN¥1.40b
Other ExpensesCN¥991.97m
EarningsCN¥409.39m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Apr 24, 2024

Earnings per share (EPS)0.64
Gross Margin64.02%
Net Profit Margin18.70%
Debt/Equity Ratio1.7%

How did 300639 perform over the long term?

See historical performance and comparison

Dividends

3.4%

Current Dividend Yield

37%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.